What is Amylyx Pharmaceuticals, Inc.'s AOCI?

Amylyx Pharmaceuticals, Inc. (AMLX) reported AOCI of $240K in Q1 2026.

What is the long-term trend for Amylyx Pharmaceuticals, Inc.'s AOCI?

Over 4 years (2021 to 2025), Amylyx Pharmaceuticals, Inc.'s AOCI has grown at a 158.8% compound annual growth rate (CAGR), from $9K to $404K.

Accumulated gains and losses bypassing the income statement — unrealized investment gains/losses, currency translation, pension adjustments, and hedge results.

Amylyx Pharmaceuticals, Inc. AMLX AOCI

AOCI at other companies

MBX Biosciences, Inc.MBX

-$606K-1,243%

Viking TherapeuticsVKTX

-$856K-296%

Beam TherapeuticsBEAM

-$1.07M-769%

Crinetics PharmaceuticalsCRNX

-$1.25M-163%

Agios PharmaceuticalsAGIO

-$314K-186%

Rhythm Pharmaceuticals, Inc.RYTM

$444K+971%

Other financials

Income statement

See full

Revenue-—

Gross profit-—

Operating income-$43.8M-15.8%

Net income-$41.3M-15.0%

EPS (diluted)-$0.37+11.9%

Balance sheet

See full

Cash & equivalents$229.1M+283%

Total debt$5.6M+307%

Total equity$273.2M+35.6%

Total assets$293.6M+33.7%

Cash flow

See full

Operating cash flow-$36.9M+7.4%

CapEx$86.0K+330%

Free cash flow-$28.0M+52.6%

Valuation

See full

Market cap$1.89B+390%

Profitability

See full

Gross margin100%+6.9pp

Operating margin-47,349.8%-47,409pp

Net margin-45,096.2%-45,152pp

FCF margin-39,826.7%-39,847pp

Returns & leverage

See full

Return on equity-63.3%-12.2pp

Debt / equity0×0.0×

Current ratio17.9×+5.8×

Where this comes from

Reported directly by Amylyx Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax.

The official record: Amylyx Pharmaceuticals, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Amylyx Pharmaceuticals, Inc.'s aoci.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Amylyx Pharmaceuticals, Inc.'s AOCI?: Amylyx Pharmaceuticals, Inc. (AMLX) reported AOCI of $240K in Q1 2026.
What is the long-term trend for Amylyx Pharmaceuticals, Inc.'s AOCI?: Over 4 years (2021 to 2025), Amylyx Pharmaceuticals, Inc.'s AOCI has grown at a 158.8% compound annual growth rate (CAGR), from $9K to $404K.
What does AOCI mean?: Accumulated gains and losses bypassing the income statement — unrealized investment gains/losses, currency translation, pension adjustments, and hedge results.